This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Dr Thompson and colleagues¹ reported that 7% of cases of statin-induced rhabdomyolysis in the US Food and Drug Administration (FDA) Qscan database from November 1997 through March 2000 were associated with a coprescription for macrolide antibiotics. Such coprescriptions, however, only accounted for 3% of such incidents between January 1990 and March 2002. It is unclear whether this represents a class effect or is due only to specific macrolide antibiotics.

Because the 3 most commonly prescribed macrolides differ from one another in their effects on the cytochrome system,² there may not be single macrolide class effect for the risk of statin-associated rhabdomyolysis. Erythromycin, a group 1 agent, strongly binds and inhibits cytochrome P-450 (CYP) 3A4. Clarithromycin is a group 2 agent and exhibits less affinity for CYP 3A4 than does erythromycin. Group 3 agents include azithromycin, which has been found to have little interference with the CYP system.² . . . [Full Text of this Article]

Join Y. Luh, MD
Departments of Surgery and Internal Medicine

Bernard M. Karnath, MD
Department of Internal Medicine
University of Texas Medical Branch at Galveston

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Statin-Associated Myopathy
, , and
JAMA. ;289():1681-1690.
FULL TEXT  

Issues in Statin-Associated Myopathy

JAMA. ;290():888-888.
FULL TEXT  

Issues in Statin-Associated Myopathy--Reply
, , and
JAMA. ;290():888-889.
FULL TEXT